A replication competent oncolytic group B adenovirus EnAd comprising: two or more transgenes, a first transgene comprising a DNA sequence encoding B7-1 protein, and an additional transgene encoding an anti-CD3 antibody or binding fragment thereof, pharmaceutical compositions comprising said virus and use of any one of the same in treatment, in particular the treatment of cancer.
